Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine/Naloxone Sublingual Tablets for Opioid Dependence Maintenance (Phase II)
CTR20130360Phase 2Active
- Sponsor
- Nanchang Lijian Pharmaceutical
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine, naloxone in opioid use disorder (OUD), sponsored by Nanchang Lijian Pharmaceutical. Started May 2014; status: active.
02
Drugs
buprenorphinenaloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on CTR20130360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130360.